Once-daily everolimus administration is a further option to improve compliance to immunosuppressive therapy. We randomized 23 stable kidney transplant recipients already on everolimus therapy to receive a single daily morning dose or to continue the twice-daily regimen. The everolimus levels evaluated after 2 weeks showed a slight reduction from 5.13 +/- 1.61 ng/mL at baseline to 4.76 +/- 1.61 ng/mL, which was not statistically significant. After 2 weeks we also evaluated cyclosporine (CsA) levels together with renal function parameters, neither of which showed episodes, any difference between the converted versus twice-daily groups. We did not record any adverse event, such as an infection, an acute rejection episode, or graft loss, over the 6-month study period. Single dosing of everolimus is possible and safe and may achieve better patient compliance to multiple-drug immunosuppressive therapy.

Carmellini, M., Collini, A., Ruggieri, G., & Bernini, M. (2010). Conversion of stable kidney transplant recipients from a twice-daily to once-daily everolimus regimen. TRANSPLANTATION PROCEEDINGS, 42(4), 1312-1313 [10.1016/j.transproceed.2010.03.098].

Conversion of stable kidney transplant recipients from a twice-daily to once-daily everolimus regimen.

CARMELLINI, MARIO;RUGGIERI, GIULIANA;
2010

Abstract

Once-daily everolimus administration is a further option to improve compliance to immunosuppressive therapy. We randomized 23 stable kidney transplant recipients already on everolimus therapy to receive a single daily morning dose or to continue the twice-daily regimen. The everolimus levels evaluated after 2 weeks showed a slight reduction from 5.13 +/- 1.61 ng/mL at baseline to 4.76 +/- 1.61 ng/mL, which was not statistically significant. After 2 weeks we also evaluated cyclosporine (CsA) levels together with renal function parameters, neither of which showed episodes, any difference between the converted versus twice-daily groups. We did not record any adverse event, such as an infection, an acute rejection episode, or graft loss, over the 6-month study period. Single dosing of everolimus is possible and safe and may achieve better patient compliance to multiple-drug immunosuppressive therapy.
Carmellini, M., Collini, A., Ruggieri, G., & Bernini, M. (2010). Conversion of stable kidney transplant recipients from a twice-daily to once-daily everolimus regimen. TRANSPLANTATION PROCEEDINGS, 42(4), 1312-1313 [10.1016/j.transproceed.2010.03.098].
File in questo prodotto:
File Dimensione Formato  
Conversion of stable kidney transplant recipients from a twice-daily to once-daily everolimus regimen..pdf

non disponibili

Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 89.77 kB
Formato Adobe PDF
89.77 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11365/20538
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo